Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
BIOLOGICAL: IMNN-001|DRUG: Carboplatin|DRUG: Paclitaxel
PFS, The primary objective of the study is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus IMNN-001 versus standard NACT., The primary analysis for PFS will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later.
Overall Survival, Overall survival is defined as the time (in months) from the date of randomization to the date of death., Randomization to date of death, for up to 3 years from LPI
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.